global countertops market size, by value · 2019-03-04 · table of content s.no particulars page...

Global Haemophilia Market : Analysis By Type (Haemophilia A,

Haemophilia B), By Treatment (On-demand , Prophylaxis), By Region, By

Country (2019 Edition): Opportunities and Forecasts (2013-2023)

• By Type- Haemophilia A and Haemophilia B

• By Treatment – On-demand and Prophylaxis

• By Region - North America, Europe, Asia Pacific, ROW.

• By Country - U.S, Canada, U.K, Germany, Japan, China,

India, Brazil.

February 2019

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Glo

bal

Market

(By Value)

By Type,

By Value

Haemophilia A

Haemophilia B

By Treatment,

By Value

On-demand

Prophylaxis

Regio

nal

By Type,

By Value

Haemophilia A

Haemophilia B

By Treatment,

By Value

On-demand

Prophylaxis

Countr

y

By Type,

By Value

Haemophilia A

Haemophilia B

By Treatment,

By Value

On-demand

Prophylaxis

Company Analysis Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension Therapeutics, Shire, CSL Behring, Alnylam

Pharmaceuticals.

Regional Analysis North America, Europe, APAC and ROW

Country Analysis U.S, Canada, U.K., Germany, Japan, China, India, Brazil

Historical Forecast

Scope of the Report – Global Haemophilia Market

2

Table of Content

S.No Particulars Page No.

1. Research Methodology 24

2. Executive Summary 25

3. Strategic Recommendation 26

3.1 Oral administration of drugs for haemophilia treatment 27

3.2 Use of gene therapy technology to combat disease 28

3.2 APAC region to witness augmented growth in the forecast period 29

4. Haemophilia Outlook 30

5. Global Haemophilia Market: Growth and Forecast 36

5.1 By Value (2013-2017) 37

5.2 By Value (2018-2023) 38

6. Global Haemophilia Market: Segmental Analysis 47

3

Table of Content


6.1 Global Haemophilia Market Size, By Type: Breakdown (%) 49

6.1.1 Global Haemophilia Market Size, By Type, 2017 (%) 49

6.1.2 Global Haemophilia Market Size, By Type, 2023 (%) 50

6.2 Global Haemophilia A Market, By Value (2013-2023) 51

6.3 Global Haemophilia B Market, By Value (2013-2023) 52

6.4 Global Haemophilia Market Size, By Treatment : Breakdown (%) 54

6.4.1 Global Haemophilia Market Size, By Treatment, 2017 (%) 54

6.4.2 Global Haemophilia Market Size, By Treatment, 2023 (%) 55

6.5 Global On- demand Haemophilia Market, By Value (2013-2023) 56

6.6 Global Prophylaxis Market, By Value (2013-2023) 57

7. Global Haemophilia Market: Regional Analysis 58

4

Table of Content


7.1 Global Haemophilia Market Size, By Region : Breakdown (%) 60

7.1.1 Global Haemophilia Market Size, By Region, 2017 (%) 60

7.1.2 Global Haemophilia Market Size, By Region, 2023 (%) 61

7.2 North America Haemophilia Market: Growth and Forecast 62

7.2.1 By Value (2013-2017) 63

7.2.2 By Value (2018-2023) 64

7.2.3 By Type, By Value (2013-2017) 70

7.2.4 By Type, By Value (2018-2023) 71

7.2.5 By Treatment, By Value (2013-2017) 72


7.3 North America Haemophilia Market: Country Analysis (U.S and Canada) 74

5

Table of Content

S. No. Particulars Page No.

7.3.1 U.S Haemophilia Market, By Value (2013-2023) 76

7.3.2 U.S Haemophilia Market, By Type, By Value (2013-2017) 82

7.3.3 U.S Haemophilia Market, By Type, By Value (2018-2023) 83

7.3.4 U.S Haemophilia Market, By Treatment, By Value (2013-2017) 84

7.3.5 U.S Haemophilia Market, By Treatment, By Value (2018-2023) 85

7.3.6 Canada Haemophilia Market, By Value (2013-2023) 87

7.3.7 Canada Haemophilia Market, By Type, By Value (2013-2017) 92

7.3.8 Canada Haemophilia Market, By Type, By Value (2018-2023) 93

7.3.9 Canada Haemophilia Market, By Treatment, By Value (2013-2017) 94

7.3.10 Canada Haemophilia Market, By Treatment, By Value (2018-2023) 95

7.4 Europe Haemophilia Market: Growth and Forecast 96

6

Table of Content


7.4.1 By Value (2013-2017) 97

7.4.2 By Value (2018-2023) 98

7.4.3 By Type, By Value (2013-2017) 105

7.4.4 By Type, By Value (2018-2023) 106



7.5 Europe Haemophilia Market: Country Analysis (U.K and Germany) 109

7.5.1 U.K Haemophilia Market, By Value (2013-2023) 111

7.5.2 U.K Haemophilia Market, By Type, By Value (2013-2017) 116

7.5.3 U.K Haemophilia Market, By Type, By Value (2018-2023) 117

7.5.4 U.K Haemophilia Market, By Treatment, By Value (2013-2017) 118

7

Table of Content


7.5.5 U.K Haemophilia Market, By Treatment, By Value (2018-2023) 119

7.5.6 Germany Haemophilia Market, By Value (2013-2023) 121

7.5.7 Germany Haemophilia Market, By Type, By Value (2013-2017) 126

7.5.8 Germany Haemophilia Market, By Type, By Value (2018-2023) 127

7.5.9 Germany Haemophilia Market, By Treatment, By Value (2013-2017) 128

7.5.10 Germany Haemophilia Market, By Treatment, By Value (2018-2023) 129

7.6 APAC Haemophilia Market: Growth and Forecast 130

7.6.1 By Value (2013-2017) 131

7.6.2 By Value (2018-2023) 132

7.6.3 By Type, By Value (2013-2017) 139

7.6.4 By Type, By Value (2018-2023) 140

8

Table of Content




7.7 APAC Haemophilia Market: Country Analysis (Japan, India and China) 144

7.7.1 Japan Haemophilia Market, By Value (2013-2023) 145

7.7.2 Japan Haemophilia Market, By Type, By Value (2013-2017) 150

7.7.3 Japan Haemophilia Market, By Type, By Value (2018-2023) 151

7.7.4 Japan Haemophilia Market, By Treatment, By Value (2013-2017) 152

7.7.5 Japan Haemophilia Market, By Treatment, By Value (2018-2023) 153

7.7.6 India Haemophilia Market, By Value (2013-2023) 155

7.7.7 India Haemophilia Market, By Type, By Value (2013-2017) 162

7.7.8 India Haemophilia Market, By Type, By Value (2018-2023) 163

9

Table of Content


7.7.9 India Haemophilia Market, By Treatment, By Value (2013-2017) 164

7.7.10 India Haemophilia Market, By Treatment, By Value (2018-2023) 165

7.7.11 China Haemophilia Market, By Value (2013-2023) 167

7.7.12 China Haemophilia Market, By Type, By Value (2013-2017) 173

7.7.13 China Haemophilia Market, By Type, By Value (2018-2023) 174

7.7.14 China Haemophilia Market, By Treatment, By Value (2013-2017) 175

7.7.15 China Haemophilia Market, By Treatment, By Value (2018-2023) 176

7.8 ROW Haemophilia Market: Growth and Forecast 177

7.8.1 By Value (2013-2017) 178

7.8.2 By Value (2018-2023) 178

7.8.3 By Type, By Value (2013-2017) 184

10

Table of Content


7.8.4 By Type, By Value (2018-2023) 184



7.9 ROW Haemophilia Market: Country Analysis (Brazil) 188

7.9.1 Brazil Haemophilia Market, By Value (2013-2023) 190

7.9.2 Brazil Haemophilia Market, By Type, By Value (2013-2017) 194

7.9.3 Brazil Haemophilia Market, By Type, By Value (2018-2023) 195

7.9.4 Brazil Haemophilia Market, By Treatment, By Value (2013-2017) 196

7.9.5 Brazil Haemophilia Market, By Treatment, By Value (2018-2023) 197

8. Global Haemophilia Market Dynamics 198

8.1 Global Haemophilia Market Drivers 199

11

Table of Content


8.2 Global Haemophilia Market Restraints 203

9. Global Haemophilia Market Trends 206

10. Porter Five Force Analysis 211

11. SWOT Analysis 213

12. Supply Chain Analysis 215

13. Competitive Landscape : 217

14. Policy and Regulatory Landscape 219

15. Company Profiling 230

15.1 Bayer 231

15.2 Novo Nordisk 233

15.3 Pfizer 235

12

Table of Content


15.4 Roche 237

15.5 Aptevo Therapeutics 239

15.6 Catalyst BioSciences 241

15.7 Dimension Therapeutics 242

15.8 Shire 243

15.9 CSL Behring 245

15.10 Alnylam Pharmaceuticals 246

16. About Us 247

13

List of Figures

Figure No. Figure Title Page No.

Figure 1: Haemophilia Genetic Inheritance 32

Figure 2: Replacement Therapy for Haemophilia 34

Figure 3: Global Haemophilia Market Size, By Value, 2013-2017 (USD Billion) 37

Figure 4: Global Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion) 38

Figure 5: Age distribution of haemophilia patients in United states, In 2017 39

Figure 6: Number of People With Hemophilia, By Top 5 Countries, 2017 40

Figure 7: Number of People With Bleeding Disorders, Worldwide, By Specific Disease, In 2017 41

Figure 8: Number of People With Hemophilia, Worldwide, By Type, In 2017 41

Figure 9: Usage of Factor VIII (IU Per Capita)*, 2017 42

Figure 10: Usage of Factor IX Per Capita (IU Per Capita)#, 2017 42

Figure 11: United States Blood Plasma Collection, 2013-2016, in Million Liters 43

Figure 12: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %) 44

Figure 13: Global Expected Healthcare Industry Outlook 45

Figure 14: Regional Expected Healthcare Industry Growth Rate By Year 2020 45

Figure 15: GDP Per Capita PPP, By Region, 2018 (in Thousand USD) 46

Figure 16: Projected global population aged 60 years & above (In Billions) 46

Figure 17: Global Haemophilia Market Size, By Type, 2017 (In %) 49

Figure 18: Global Haemophilia Market Size, By Type, 2023 (In %) 50

Figure 19: Global Haemophilia A Market, By Value, 2013-2017 (USD Billion) 51

Figure 20: Global Haemophilia A Market, By Value, Forecast, 2018-2023(USD Billion) 51

14

List of Figures Figure No. Figure Title Page No.

Figure 21: Global Haemophilia B Market, By Value, 2013-2017 (USD Billion) 52

Figure 22: Global Haemophilia B Market, By Value, Forecast, 2018-2023(USD Billion) 52

Figure 23: Global Haemophilia Market Size, By Treatment, 2017 (In %) 54

Figure 24: Global Haemophilia Market Size, By Treatment, 2023 (In %) 55

Figure 25: Global On-demand Market, By Value, 2013-2017 (USD Billion) 56

Figure 26: Global On-demand Market, By Value, Forecast, 2018-2023(USD Billion) 56

Figure 27: Global Prophylaxis Market, By Value, 2013-2017 (USD Billion) 57

Figure 28: Global Prophylaxis Market, By Value, Forecast, 2018-2023 (USD Billion) 57

Figure 29: Global Healthcare Landscape, By Select Region 59

Figure 30: Global Haemophilia Market Size, By Region, 2017 (%) 60

Figure 31: Global Haemophilia Market Size, By Region, 2023 (%) 61

Figure 32: North America Haemophilia Market Size, By Value, 2013-2017 (USD Billion) 63

Figure 33: North America Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion) 64

Figure 34: North America GDP, 2012-2017 (USD Trillion) 65

Figure 35: North America GDP per capita, current prices, 2013-2023F (In USD) 65

Figure 36: North America, Haemophilia diagnosis among children, 2017 (%) 66

Figure 37: Causes of acquired haemophilia 67

Figure 38: Percentage of patients obtaining blood, In 2017, In North America 68

Figure 39: Annualized healthcare cost per patient with haemophilia 68

Figure 40: North America Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 70

15

List of Figures


Figure 41: North America Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion) 71

Figure 42: North America Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 72

Figure 43: North America Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion) 73

Figure 44: U.S. Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 76

Figure 45: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD) 78

Figure 46: Contribution to total national health expenditures in United States, In 2017 79

Figure 47: Percentage of people with Haemophilia A in United States, In 2017 80

Figure 48: U.S., GDP (Current USD), 2013-2017 (In USD Trillion) 80

Figure 49: U.S. Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 82

Figure 50: U.S. Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 83

Figure 51: U.S. Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 84

Figure 52: U.S. Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 85

Figure 53: Canada Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 87

Figure 54: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %) 89

Figure 55: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) 89

Figure 56: Prevalence of bleeding disorder in Canada 90

Figure 57: Usage of clotting factors in Canada, In 2017 90

Figure 58: Canada Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 92

Figure 59: Canada Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 93

Figure 60: Canada Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 94

16

List of Figures

Figure No. Figure Title

Page No.

Figure 61: Canada Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 95

Figure 62: Europe Haemophilia Market Size, By Value, 2013-2017 (USD Billion) 97

Figure 63: Europe Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion) 98

Figure 64: Per Capita Health Expenditure, By Select Country, 2017 (USD) 100

Figure 65: GDP, Europe Region, By Select Country, 2017 (In Trillion USD) 100

Figure 66: Estimated distribution of per patient cost of haemophilia, Europe, In 2017 (EUR) 101

Figure 67: Breakdown of Total Health Expenditure in Europe, 2018 (%) 103

Figure 68: Major Players in Haemophilia Market in Europe 103

Figure 69: Europe Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 105

Figure 70: Europe Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion) 106

Figure 71: Europe Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 107

Figure 72: Europe Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion) 108

Figure 73: U.K Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 111

Figure 74: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD) 113

Figure 75: Haemophilia patients in United Kingdom, yearly basis comparison, In number 113

Figure 76: Prevalence of bleeding disorder in United Kingdom, In 2017 114

Figure 77: Usage of clotting factors in United Kingdom, In 2017 114

Figure 78: U.K. Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 116

Figure 79: U.K. Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 117

Figure 80: U.K. Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 118

17

List of Figures


Figure 81: U.K. Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 119

Figure 82: Germany Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 121

Figure 83: Usage of clotting factors in Germany, In 2017 123

Figure 84: Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD) 124

Figure 85: Average annual percent growth in GDP, 2016 (USD) 124

Figure 86: Germany Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 126

Figure 87: Germany Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 127

Figure 88: Germany Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 128

Figure 89: Germany Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 129

Figure 90: APAC Endoscopy Market Size, By Value, 2013-2017 (USD Billion) 131

Figure 91: APAC Endoscopy Market Size, By Value, Forecast, 2018-2023 (USD Billion) 132

Figure 92: Willingness in countries to donate blood, In 2016 134

Figure 93: World health expenditure as % of GDP 135

Figure 94: APAC, GDP, By Select Country, 2017 (In USD Trillion) 135

Figure 95: Diagnosis and treatment rates of haemophilia in APAC, In Asia, In 2017 137

Figure 96: Disparities in diagnosis of Haemophilia worldwide 137

Figure 97: APAC Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 139

Figure 98: APAC Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion) 140

Figure 99: APAC Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 141

Figure 100: APAC Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion) 142

18

List of Figures


Figure 101: Japan Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 145

Figure 102: Japan, GDP Growth Per Year, 2015-2019F (In %) 147

Figure 103: Japan Healthcare Expenditure Outlook (%) 147

Figure 104: Prevalence of bleeding disorder in Japan, In 2017 148

Figure 105: Usage of clotting factor in Japan, In 2017 148

Figure 106: Japan Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 150

Figure 107: Japan Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 151

Figure 108: Japan Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 152

Figure 109: Japan Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 153

Figure 110: India Endoscopy Market Size, By Value, 2013-2023 (USD Billion) 155

Figure 111: Countries with highest rates of haemophilia, In 2017 157

Figure 112: Key factors affecting the Indian Haemophilia Treatment Industry 158

Figure 113: India, Total Population, 2013-2023F (In Billion) 159

Figure 114: India, Share of Urban Population, 2012-2017 (In %) 159

Figure 115: India, GDP Growth Per Year, 2015-2019 (In %) 160

Figure 116: Prevalence of bleeding disorder in India, In 2017 160

Figure 117: India Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 162

Figure 118: India Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 163

Figure 119: India Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 164


19

List of Figures



Figure 122: China Healthcare Expenditure Outlook (%) 169

Figure 123: China, GDP Growth Per Year, 2015-2019 (In %) 170

Figure 124: China, Share of Urban Population, 2012-2017 (In %) 170

Figure 125: China, Total Population, 2013-2021F (In Billion) 170

Figure 126: Prevalence of bleeding disorder in China, In 2017 171

Figure 127: Age distribution for haemophilia patients in China, In 2017, In % 171

Figure 128: China Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 173

Figure 129: China Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion) 174

Figure 130: China Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 175

Figure 131: China Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion) 176

Figure 132: ROW Haemophilia Market Size, By Value, 2013-2023 (USD Billion) 178

Figure 133: Middle East and North Africa, GDP, 2012-2017 (In USD Trillion) 179

Figure 134: Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %) 179

Figure 135: Top 10 fastest growing economies, 2018, (In%) 180

Figure 136: Percentage of people with haemophilia A in Latin America, In 2017 181

Figure 137: ROW Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 184

Figure 138: ROW Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion) 185

Figure 139: ROW Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 186

Figure 140: ROW Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion) 187

20

List of Figures


Figure 141: Brazil Haemophilia Market Size, By Value, 2013-2023 (USD Million) 190

Figure 142: Brazil, GDP, 2012-2017 (In USD Trillion) 191

Figure 143: Brazil health expenditure as a share of GDP, 2016 191

Figure 144: Prevalence of bleeding disorder in Brazil 192

Figure 145: Inhibitor formation in hemophiliac patients, In Brazil, In 2017 192

Figure 146: Brazil Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion) 194

Figure 147: Brazil Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion) 195

Figure 148: Brazil Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion) 196

Figure 149: Brazil Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion) 197

Figure 150: Working of traditional factors vs. half life factors 210

Figure 151: Bayer, Sales Revenue, 2013-2017 (USD Billion) 232

Figure 152: Bayer, Sales, By Business Segment, FY ended March 2017 (%) 232

Figure 153: Bayer , Sales, By Geographic region, FY ended March 2017 (%) 232

Figure 154: Novo Nordisk, Net Sales, 2014-2018 (In Million USD) 234

Figure 155: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %) 234

Figure 156: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %) 234

Figure 157: Pfizer, Sales Revenue, 2013-2017 (USD million) 236

Figure 158: Pfizer, Sales, By Business Segment, FY ended March 2017 (In %) 236



21

List of Figures


Figure 161: Roche, Sales, By Business Segment, FY ended March 2018 (%) 238

Figure 162: Roche, By Region, FY ended March 2018 (%) 238

Figure 163: Aptevo Therapeutics, Sales Revenue, 2015-2018 (USD Million) 240

Figure 164: Shire, Sales Revenue, 2016-2017 (USD Million) 244

Figure 165: Shire, Sales, By Business Segment, FY ended March 2017 (%) 244

Figure 166: Shire, By Region, FY ended March 2017 (%) 244

22

List of Figures


Table A: Classification of haemophilia depending upon severity level

31

Table B: Treatment options for Haemophilia 33

Table C: Facts about Haemophilia 33

Table D: Types of Prophylaxis 35

Table E: Prophylaxis over On-demand 35

Table F: Advantages of Prophylaxis 66

Table G: Facts about blood donation in North America 79

Table H: Estimated Haemophilia Insights, In Europe, In 2017 102

Table I: Germany, Healthcare Related Statistics, 2017 123

Table J: Global Access to Healthcare Index, Ranking of Select Countries in Asia Pacific Region, 2017 (score out of 10) 136

Table K: Coverage of population with health insurance in Latin America, 2017, (In%) 180

Table L: Prevalence of different types of bleeding in haemophilia, In Africa, In 2018 182

Table M: Frequency of hemarthrosis in different joints in South Africa, In 2018, In % 182

Table N: Healthcare spending pattern in Brazil (In USD) 191

Table O: Recent novel gene therapy products for treating Haemophilia 208

Table P: Global Endoscopes Market, By Company Share, 2018 (%) 218

23

For our study on Global haemophilia market, we have conducted comprehensive secondary research followed

by an extensive primary research. In the process of secondary research, we have scrutinized industry

documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva)

and our internal knowledge base. In the process of primary research, we have interviewed various industry

experts across the value chain of medical device industry.

Market size of the actual period (2013-2017) has been evaluated on the basis of growth trends of the

industry in the last five years, and confirming the findings through primary research. Annual reports of the

companies were scanned to further validate the market size and to estimate the size of various other end-

user sectors. Market sizing and growth in the forecast period (2018-2023) is estimated through product

mapping, application in end-user industries, growth of allied sectors and historical growth pattern of the

industry. All the relevant data points/ statistics in the forecast period are validated through relevant and

reliable primary sources.

Report Focus: Global Haemophilia Market

- By Type (Haemophilia A Haemophilia B)

- By Treatment (On- demand, Prophylaxis)

- By Region (North America, Europe, Asia Pacific and Rest of the World)

- By Country ( U.S., Canada, U.K, Germany, India, China, Japan and Brazil).

Companies Contacted: Bayer, Novo Nordisk

Research Methodology

24

Competitive Landscape

Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension

Therapeutics, Shire, CSL Behring, Alnylam Pharmaceuticals.

Market

Drivers & Challenges

• Drivers

Increasing life expectancy.

Reduction in inhibitor formation in

severe haemophilia cases.

Emerging therapies for haemophilia.

• Challenges

High cost involved in treatment.

Lack of patient compliance.

Trend

The global haemophilia market was

valued at USD 10.25 billion in the

year 2018 with North America

leading the regional market share.

.

The global market grew at CAGR of

approximately 5.21% during the

period 2013-2017 and is expected to

grow further by CAGR 6.84% in the

forecast period 2018-2023.

Emanating gene transfer

technology.

Longer acting factor concentrates.

Executive Summary

25

Global Haemophilia Market

2013 2014 2015 2016 2017

Source: Azoth Analytics Estimates

CAGR 2013-2017

xx%

Figure 3: Global Haemophilia Market Size, By Value, 2013-2017 (USD Billion)

Xx

Xx

Xx

Xx

Xx

Increase in haemophilic neonatal population in combination with various government efforts to

control the disease has been boosting the market for haemophilia in the historic period.

26

Global Haemophilia Market

2018 2019 2020 2021 2022 2023


CAGR 2018-2023

xx%

Figure 4: Global Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion)

Xx

Xx

Xx

Xx

Xx

Increase in availability as well as type of treatments against haemophilia and reduction in

bleeding episodes is likely to drive the market in the forecast period.

27

Global Trandermal Drug Delivery Systems Replacement Devices Market, By Value

Figure 19: Global Haemophilia A Market, By Value, 2013-

2017 (USD Billion)


CAGR 2013-2017

xx%

CAGR 2018-2023

xx%

Figure 20: Global Haemophilia A Market, By Value,

Forecast, 2018-2023(USD Billion)

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Global Haemophilia A Market

Xx

Xx

Xx

Xx

Xx

Xx

Xx

28


Figure 21: Global Haemophilia B Market, By Value,

2013-2017 (USD Billion)


Figure 22: Global Haemophilia B Market, By Value,

Forecast, 2018-2023(USD Billion)

Global Haemophilia B Market

CAGR 2013-2017

xx%

CAGR 2018-2023

xx%

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Xx

Xx

Xx

Xx

Xx

Xx

Xx

29


Figure 25: Global On-demand Market, By Value, 2013-

2017 (USD Billion)


Figure 26: Global On-demand Market, By Value, Forecast,

2018-2023(USD Billion)

Global On-demand Market

CAGR 2013-2017

xx%

CAGR 2018-2023

xx%

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Xx

Xx

Xx

Xx

Xx

Xx

Xx

30


Figure 27: Global Prophylaxis Market, By Value,



Figure 28: Global Prophylaxis Market, By Value, Forecast,


Global Prophylaxis Market

CAGR 2013-2017

xx%

CAGR 2018-2023

xx%

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Xx

Xx

Xx

Xx

Xx

Xx

Xx

31

North America Haemophilia Market Overview


Heavy investments in medical research and development in addition to high per capita expenditure on

healthcare have been the key factors backing the regional Haemophilia market.

Figure 32: North America Haemophilia Market Size, By Value, 2013-2017 (USD Billion)

2013 2014 2015 2016 2017

CAGR 2013-2017

xx%

Xx

Xx

Xx

Xx

Xx

32

North America Haemophilia Market Overview


Figure 33: North America Haemophilia Market Size, By Value, Forecast, 2018-2023 (USD Billion)

Noteworthy growth in the regional market is attributed to upcoming gene therapy products and shift in

demand from on therapy to prophylaxis therapy.

2013 2014 2015 2016 2017

CAGR 2013-2017

xx%

Xx

Xx

Xx

Xx

Xx

33


Figure 40: North America Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)

CAGR 2013-2017

Haemophilia A: xx%

Haemophilia B: xx%

North America Haemophilia Market, By Type

2013 2014 2015 2016 2017

Haemophilia A xx xx xx xx xx

Haemophilia B xx xx xx xx xx

2013 2014 2015 2016 2017

Haemophilia A Haemophilia B

Xx

Xx

Xx

Xx

34


Figure 41: North America Haemophilia Market: By Type, By Value, 2018E-2023F (USD Billion)

North America Haemophilia Market, By Type

2018 2019 2020 2021 2022 2023

Haemophilia A xx xx xx xx xx xx

Haemophilia B xx xx xx xx xx xx

2018 2019 2020 2021 2022 2023


CAGR 2018-2023

Haemophilia A : xx%

Haemophilia B : xx%

Xx

Xx

Xx

Xx

Xx

35


Figure 42: North America Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)

CAGR 2013-2017

On-demand: xx%

Prophylaxis : xx%

North America Haemophilia Market, By Treatment

2013 2014 2015 2016 2017

On-demand xx xx xx xx xx

Prophylaxis xx xx xx xx xx

2013 2014 2015 2016 2017

on demand prophylaxis

Xx

Xx

Xx

Xx

Xx

36


Figure 43: North America Haemophilia Market: By Treatment, By Value, 2018E-2023F (USD Billion)

North America Haemophilia Market, By Treatment

2018 2019 2020 2021 2022 2023


CAGR 2018-2023

On-demand: xx%

Prophylaxis: xx%

2018 2019 2020 2021 2022 2023

On-demand xx xx xx xx xx xx

Prophylaxis xx xx xx xx xx xx

Xx

Xx

Xx

Xx

Xx

37

U.S. Haemophilia Market, By Value


Figure 44: U.S. Haemophilia Market Size, By Value, 2013-2023 (USD Billion)

CAGR 2013-2017

xx%

CAGR 2018-2023

xx%

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Xx

Xx

Xx

Xx

Xx

Xx

Xx

38


Figure 49: U.S. Haemophilia Market: By Type, By Value, 2013-2017 (USD Billion)

U.S. Haemophilia Market, By Type

CAGR 2013-2017

Haemophilia A: xx%

Haemophilia B: xx%

2013 2014 2015 2016 2017

Haemophilia A xx xx xx xx xx

Haemophilia B xx xx xx xx xx

2013 2014 2015 2016 2017


Xx

Xx

Xx

Xx

39


Figure 50: U.S. Haemophilia Market: By Type, By Value, 2018-2023 (USD Billion)

U.S. Haemophilia Market, By Type

2018 2019 2020 2021 2022 2023

Haemophilia A xx xx xx xx xx xx

Haemophilia B xx xx xx xx xx xx

2018 2019 2020 2021 2022 2023


CAGR 2018-2023

Haemophilia A : xx%

Haemophilia B : xx%

Xx

Xx

Xx

Xx

Xx

40


Figure 51: U.S. Haemophilia Market: By Treatment , By Value, 2013-2017 (USD Billion)

U.S. Haemophilia Market, By Treatment

CAGR 2013-2017

On-demand: xx%

Prophylaxis : xx%

2013 2014 2015 2016 2017

On-demand xx xx xx xx xx

Prophylaxis xx xx xx xx xx

2013 2014 2015 2016 2017


Xx

Xx

Xx

Xx

Xx

41


Figure 52: U.S. Haemophilia Market: By Treatment , By Value, 2018-2023 (USD Billion)

U.S. Haemophilia Market, By Treatment

2018 2019 2020 2021 2022 2023


CAGR 2018-2023

On-demand: xx%

Prophylaxis: xx%

2018 2019 2020 2021 2022 2023

On-demand xx xx xx xx xx xx

Prophylaxis xx xx xx xx xx xx

Xx

Xx

Xx

Xx

Xx

42

About Azoth Analytics Pvt Ltd.

Azoth Analytics (ISO 9001:2015) is a business research and analytics company that creates in-depth research reports and provides customized research

solutions and consulting services. An ISO 9001:2015 certified company, Azoth Analytics adheres to international quality management standard and has strong

commitment to a culture of continuous improvement. The business research and market analysis of Azoth Analytics helps organizations across different

industry verticals solve their business problems. Strategic market sizing and data dredging techniques include secondary research, and primary research

(interviews with management personnel and industry experts). Azoth Analytics provide syndicated and customized market research reports on different

verticals including pharmaceutical and healthcare, oil and gas and power, chemicals, automotive, technology, FMCG, food & beverages and media sectors.

Recent Azoth Analytics Reports

• Global Advanced Wound Care Market: Analysis By Type (Advanced Wound Dressings, Wound Therapy Devices, Wound Biologics), By

Application (Chronic Wounds, Acute Wounds), By End-User, By Region, By Country (2018 Edition): Opportunities and Forecasts (2018-

2023)

• Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition):

Forecast to 2023 - By Indication (Open Angle, Closed Angle, Secondary, Congenital, Others), By Drug Class (Prostaglandin Analogs,

Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors)

• Global Transdermal Drug Delivery System Market: Analysis By Type (Patches, Gels), By Technique (Ionophoresis, Electroporation,

Sonophoresis, Others), By End-User, By Region, By Country (2018 Edition): Trends, Opportunities and Forecast (2013-2023)

43

global countertops market size, by value · 2019-03-04 · table of content s.no particulars page...

Documents